tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)
PremiumThe FlyJasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)
7d ago
Jasper Therapeutics Announces Major Corporate Reorganization
Premium
Company Announcements
Jasper Therapeutics Announces Major Corporate Reorganization
1M ago
Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria
Premium
The Fly
Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria
1M ago
Hold Rating for Jasper Therapeutics Amid Uncertainties in Briquilimab’s Clinical Trials and Competitive Challenges
PremiumRatingsHold Rating for Jasper Therapeutics Amid Uncertainties in Briquilimab’s Clinical Trials and Competitive Challenges
1M ago
Cantor cuts Jasper Therapeutics to Neutral after briquilimab update
Premium
The Fly
Cantor cuts Jasper Therapeutics to Neutral after briquilimab update
1M ago
Jasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Premium
The Fly
Jasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
1M ago
Jasper Therapeutics price target lowered to $20 from $40 at H.C. Wainwright
PremiumThe FlyJasper Therapeutics price target lowered to $20 from $40 at H.C. Wainwright
1M ago
Jasper Therapeutics Reports Promising Briquilimab Study Results
Premium
Company Announcements
Jasper Therapeutics Reports Promising Briquilimab Study Results
1M ago
Jasper Therapeutics to stop ETESIAN study due to drug product lot issue
Premium
The Fly
Jasper Therapeutics to stop ETESIAN study due to drug product lot issue
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100